FDA Approves First Gene Therapy for Bladder Cancer
PLUS: New Trial for Hereditary Angioedema
Hi friends 👋🏼,
Here are the top stories in the world of medical biology:
First Gene Therapy for Bladder Cancer Approved READER REQUEST
Phase I/II Clinical Trial Initiated for Hereditary Angioedema
CRISPR Shows Promise for Retinitis Pigmentosa READER REQUEST
TALENs as Targeted Therapy for HPV-Induced Cancer READER REQUEST
📣 First Gene Therapy for Bladder Cancer Approved
What is non-muscle invasive bladder cancer (NMIBC)? NMIBC is a form of bladder cancer that is present in the surface layers of the bladder - it has not invaded deeper into the bladder or other parts of the body. Currently, the first treatment option for NMIBC is to add Bacillus Calmette-Guerin (BCG), a bacteria, through a catheter. Yes, you read that right - BCG is a bacteria that does not cause serious disease and it is added into the bladder to help “turn on” the immune system in the bladder and kill the bladder cancer. 🤯 However, BCG therapy will fail in 40-50% of patients leaving them with only one other option: removal of the whole bladder.
1/ Adstiladrin® is the first gene therapy approved for BCG-unresponsive NMIBC.
2/ The FDA approval of Adstiladrin® was based on the results of a Phase 3 clinical trial where 51% of patients had a complete response to the gene therapy eliminating their bladder cancer and remaining free of cancer recurrence for at least 12 months.
How Adstiladrin® gene therapy works 👇🏼
Subscribe to The Cure to read the rest.
Become a paying subscriber of The Cure to get access to this post and other subscriber-only content.
Already a paying subscriber? Sign In